Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Improving Surgical Decision-making in Young Women With Breast Cancer

26 juni 2020 bijgewerkt door: Shoshana M. Rosenberg, Dana-Farber Cancer Institute

The overall goal of this study is to qualitatively assess the surgical decision-making process from both the patient and physician perspective

  1. Conduct short in-person interviews with young women prior to surgery
  2. Conduct focus groups with breast cancer survivors about their surgical decision and experience
  3. Interview surgical oncologists, plastic surgeons, medical and radiation oncologists about their experiences and how they communicate with breast cancer patients about local therapy decisions
  4. To survey women about surgical decision-making prior to and after their consult in conjunction with pilot testing of a web-based decision aid to support high quality surgical decision-making in newly diagnosed young women with breast cancer.

Studie Overzicht

Gedetailleerde beschrijving

Breast cancer in young women: Breast cancer is the most common cancer diagnosed in women younger than age 40 in the United States, with approximately 14,000 new cases each year. Young women face unique psychosocial challenges, most notably fertility, sexuality, and image concerns and are at a life stage where education, career, and family are important priorities. Concern about these issues may contribute to the greater psychosocial distress seen in younger women at both diagnosis and in follow-up compared with older women. Importantly, these concerns may also influence treatment decisions including receipt of chemotherapy, adherence to endocrine therapy, and surgical decisions. Thus, attending to the unique issues of young women may enhance not only quality of care and quality of life (QOL) but also potentially disease outcomes.

Surgical management of breast cancer: Standard loco-regional management of breast cancer entails partial mastectomy (i.e., breast conserving surgery) followed by radiation or mastectomy with or without radiation. The decision depends on a number of factors including extent of disease, family history, BRCA mutation status, and personal preference. In recent years, an increasing number of women have elected to undergo contralateral prophylactic mastectomy (CPM) in conjunction with surgery of the affected breast (usually choosing bilateral mastectomy), despite a lack of clear evidence for survival benefit from this procedure in the vast majority of women. In weighing the benefits and risks of CPM, one must consider the absolute risk reduction of a new primary breast cancer (usually relatively modest in the average risk survivor), the long and short-term risks of this additional surgery including potential complications (bilateral mastectomy is associated with a greater risk of surgical complications) and the impact on QOL. At the same time, one must consider the competing risk of systemic recurrence of a woman's initial breast cancer. Young women, in particular, have the greatest risk of systemic recurrence and death from their original cancer, lowering the likelihood of benefit of CPM in preventing a new primary breast cancer. However, while CPM rates have increased among all breast cancer patients, increased rates of CPM are particularly pronounced among the youngest women with breast cancer, with several studies identifying young age at diagnosis as one of the strongest determinants of CPM.Physicians and researchers have been observing and discussing this trend for a number of years and yet little has been done to intervene.

The goal of the proposed research is to better understand and improve the surgical decision process in young women with breast cancer. Using qualitative research methods, we will comprehensively assess patient experiences - both patients who have had CPM and patients who did not - as well as physician perspectives regarding this decision. Based on these findings, the investigators will determine how to best improve the quality of the process, e.g., by correcting misperceptions, setting realistic expectations regarding the impact of surgery (including reconstruction) on QOL, improving communication with health care providers, and better management of anxiety surrounding diagnosis. This qualitative research is designed to build on prior quantitative analyses, by gaining an in depth perspective through focus groups and interviews, about certain issues identified as impacting the surgical decision process, including anxiety, fear of recurrence, and patient-physician communication.

Collectively, results from the qualitative assessment will inform a future phase of this research involving the design and subsequent development of a decision aid to help women make informed decisions about their breast cancer surgery.

The goal of this second phase of the research is to survey women about surgical decision-making prior to and after their consult in conjunction with pilot testing of a web-based decision aid to support high quality surgical decision-making in newly diagnosed young women with breast cancer.

Studietype

Observationeel

Inschrijving (Werkelijk)

145

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 80 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Vrouw

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

Young Women with a history of breast cancer and providers who care for them.

Beschrijving

Inclusion Criteria:

Patients for key informant interviews-

  1. Newly diagnosed women with Stage 0-3 breast cancer
  2. Between the ages of 18 and 40 who are seen at DFCI and have not yet had their primary breast cancer surgery.

Patients for focus groups:

  1. diagnosis of Stage 0-3 breast cancer at age 40 and younger
  2. currently between the ages of 18-43
  3. English-speaking
  4. 1-3 years from diagnosis
  5. Had breast cancer surgery
  6. no evidence of recurrent or metastatic disease.

Providers:

Must care for women who have breast cancer. Can be surgeons, surgical oncologists, medical and/or radiation oncologists

Patients for Surgical Decision Making Pilot

  1. Women with newly-diagnosed, unilateral Stage 0-3 breast cancer
  2. Between the ages of 18 and 40
  3. Who are seen by a surgeon at DFCI/BWH or Faulkner Hospital
  4. English speaking
  5. Have not yet had their primary breast cancer surgery

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Observatiemodellen: Ander
  • Tijdsperspectieven: Ander

Cohorten en interventies

Groep / Cohort
Interventie / Behandeling
Key Informant interviews
20 in-person or phone qualitative interviews with patients.
qualitative data collection
Focus Groups
four qualitative focus groups of 6-10 women each.
qualitative data collection
Physician Interviews
physician qualitative interviews over the telephone.
qualitative data collection
Usual care cohort (pilot)
50 women who will be surveyed before and after their surgical consult
survey pre and post-surgical consult
Decision aid cohort (pilot)
50 women who will be surveyed before and after their surgical consult and will also be sent a web-based decision aid
survey pre and post-surgical consult
web-based decision aid post-surgical consult

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Thematic summary from the data gathered from the use of a moderator guide (series of probing questions) that inquires about the experiences surrounding the surgical decision-making process from both the patient and physician perspective
Tijdsspanne: 1 year
The goal of the proposed research is to better understand and improve the surgical decision process in young women with breast cancer. Using qualitative research methods, we will comprehensively assess patient experiences - both patients who have had CPM and patients who did not - as well as physician perspectives regarding this decision.
1 year
Breast cancer knowledge
Tijdsspanne: 2 weeks
Knowledge will be assessed using selected questions from the Breast Cancer Surgery Decision Quality Instrument (BCS-DQI), an instrument designed to evaluate the quality of breast cancer treatment decisions as well as additional true/false questions related to side effects of radiation.
2 weeks
Decisional conflict
Tijdsspanne: 2 weeks
Decisional conflict will be measured with the SURE scale. The SURE scale is composed of four items from the Decisional Conflict Scale that measure patients' uncertainty about which treatment choice and factors contributing to uncertainty.
2 weeks
Anxiety
Tijdsspanne: 2 weeks
Anxiety will be assessed using the PROMIS Emotional Distress - Anxiety - Short Form.
2 weeks
Treatment goals and preferences
Tijdsspanne: 2 weeks
have been adapted from the BCS-DQI. We will ask women to mark on a scale (not important - very important) the importance of several reasons in relation to their decision about surgery as well as concerns (not all concerned-very concerned) about local therapy.
2 weeks
Perception of decision process
Tijdsspanne: 2 weeks
Perception of the decision process will be assessed with an adapted version of the Control Preferences Scale.
2 weeks

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Usability of decision aid (DA)
Tijdsspanne: 2 weeks-1 month
Assessment of what patients did and did not like about the DA, ways they think the DA can be improved, and how they felt the DA affected communication with their physician.
2 weeks-1 month

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Shoshana Rosenberg, ScD, Dana-Farber Cancer Institute

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

19 februari 2016

Primaire voltooiing (Werkelijk)

10 april 2020

Studie voltooiing (Werkelijk)

10 april 2020

Studieregistratiedata

Eerst ingediend

20 december 2015

Eerst ingediend dat voldeed aan de QC-criteria

29 december 2015

Eerst geplaatst (Schatting)

31 december 2015

Updates van studierecords

Laatste update geplaatst (Werkelijk)

29 juni 2020

Laatste update ingediend die voldeed aan QC-criteria

26 juni 2020

Laatst geverifieerd

1 juni 2020

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • 15-288
  • 1K01HS023680-01A1 (Amerikaanse AHRQ-subsidie/contract)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

Nee

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren